Genome Engineering Market Size, Share, Trends - Analysis Report 2022
According to research report the global Genome Engineering Market is projected to reach USD 6.28 billion by 2022 from USD 3.19 billion in 2017, at a CAGR of 14.5% during the forecast period.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=231037000
The
key factors propelling the growth of this genome editing market are
rising government funding and growth in the number of genomics projects,
high prevalence of infectious diseases and cancer, technological
advancements, increasing production of genetically modified crops, and
growing application areas of genomics.
In 2017, North America is
projected to have the highest growth rate during the forecast period.
Factors such as the development of gene therapy in the US, increasing
use of genetically modified crops, rising prevalence of infectious
diseases and cancer, and rising availability of research grants and
funding are propelling market growth in North America.
The global
genome editing market, by application, is segmented into cell line
engineering, genetic engineering, and other applications (diagnostics
and therapeutics). The cell line engineering segment is estimated to
register the highest growth rate during the forecast period. Factors
such as increasing funding from governments and private organizations,
growing industry focus on stem cell research, and increasing global
awareness about stem cell therapies through various organizations are
driving the growth of the cell line engineering segment.
Based on
end user, the global genome engineering market is segmented into
biotechnology & pharmaceutical companies, academic & government
research institutes, and contract research organizations. The
biotechnology & pharmaceutical companies’ segment is estimated to
register the highest growth rate during the forecast period. The
increasing prevalence of infectious diseases and cancer are driving
research activities worldwide; this is expected to drive the demand for
genome editing in biotechnology & pharmaceutical companies.
Based
on technology, the genome engineering market is segmented into CRISPR,
TALEN, ZFN, antisense, and other technologies (PiggyBac, Flp-In, Adenine
Base Editor (ADE), and Jump-In). The CRISPR segment is expected to
register the highest growth during the forecast period. The ease of use
associated with the CRISPR technology is a significant advantage over
ZFN and TALEN, especially in generating a large set of vectors to target
numerous sites or even genome-wide libraries is one of the major
factors driving the growth of this segment.
Some of the major
players in the genome engineering market are Thermo Fisher Scientific
(US), Merck (Germany), Horizon Discovery Group (UK), GenScript (US),
Sangamo BioSciences (US), Integrated DNA Technologies (US), Lonza Group
(Switzerland), New England Biolabs (US), OriGene Technologies (US),
Transposagen Biopharmaceuticals (US), Editas Medicine (US), and CRISPR
Therapeutics (Switzerland).
Request Free Report Sample: https://www.marketsandmarkets.com/requestsampleNew.asp?id=231037000
Comments
Post a Comment